N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.

Abstract:

:The in vitro effects of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR, fenretinide) on primary B-cell chronic lymphocytic leukemia (CLL) cells from previously untreated CLL patients were investigated. 4HPR promoted the intrinsic apoptotic pathway by reactive oxygen species (ROS) generation and was accompanied by drop of Mcl-1 protein expression. The latter was not attributable to transcriptional downregulation but to protein degradation mediated by jun N-terminal kinase activation, and likely by NF-kB downregulation and Noxa upregulation. CLL cells stimulated in vitro with CD40L did not increase 4HPR chemoresistance if activation was accompanied by proliferation. Intra-patient analysis confirmed that the proliferating pool of CLL cells was more sensitive to the cytotoxic action of 4HPR than the activated but resting CLL subpopulation. The different 4HPR susceptibility of the two subpopulations was associated with higher Noxa expression in proliferating CLLs. Combination experiments revealed that 4HPR strongly potentiated ABT-737 cytotoxicity, especially in proliferating CLL cells that displayed amplified chemoresistance to ABT-737 alone. Synergic cytotoxicity was also demonstrated in combination with fludarabine, in both resting and stimulated CLL samples. This study entitles 4HPR to be assayed as a chemotherapeutic adjuvant for the treatment of CLL.

journal_name

Leukemia

journal_title

Leukemia

authors

Bruno S,Ghiotto F,Tenca C,Mazzarello AN,Bono M,Luzzi P,Casciaro S,Recchia A,Decensi A,Morabito F,Fais F

doi

10.1038/leu.2012.98

subject

Has Abstract

pub_date

2012-10-01 00:00:00

pages

2260-8

issue

10

eissn

0887-6924

issn

1476-5551

pii

leu201298

journal_volume

26

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

    abstract::Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In uni...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.109

    authors: Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

    更新日期:2011-09-01 00:00:00

  • Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.

    abstract::Bryostatin 1 is a macrocyclic lactone activator of protein kinase C which has displayed promising antileukemic potential in pre-clinical studies. We have assessed the effect of bryostatin 1 on the in vitro clonogenic response of leukemic myeloblasts obtained from 12 patients with acute non-lymphocytic leukemia to reco...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Grant S,Pettit GR,Howe C,McCrady C

    更新日期:1991-05-01 00:00:00

  • Gene therapy against retroviral diseases.

    abstract::Eventually, gene therapy may be a valid option for chronic viral infections, including retroviral infections. Human retroviral diseases fit two categories: (1) those that result from a monoclonal outgrowth of a human T-cell leukemia virus type I (HTLV-I)-infected cell, as in the case of adult T cell leukemia (ATL); an...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Essex M,Matsuda Z,Yu X,Lee TH

    更新日期:1995-10-01 00:00:00

  • Rearrangement of the retinoic acid receptor gene in acute promyelocytic leukemia.

    abstract::The retinoic acid receptor-alpha (RAR-alpha) gene was previously localized to chromosome 17q21, a region close to the t(15;17) (q22;q21) abnormality in acute promyelocytic leukemia (APL). We used the RAR-alpha gene as a probe and found that eight of nine APL patient samples with t(15;17) (q22;q21) showed rearranged ba...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Chang KS,Trujillo JM,Ogura T,Castiglione CM,Kidd KK,Zhao SR,Freireich EJ,Stass SA

    更新日期:1991-03-01 00:00:00

  • Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.

    abstract::The long-term results in 130 patients with newly diagnosed acute myelogenous leukemia treated with continuous infusion high-dose ara-C (1.5 gm/m2/day x 4 days, CIHDAC) were compared with those in 264 patients treated in previous studies with standard dose ara-C (70-90 mg/m2/d x 7 days) plus either adriamycin (Ad-OAP),...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Ghaddar HM,Plunkett W,Kantarjian HM,Pierce S,Freireich EJ,Keating MJ,Estey EH

    更新日期:1994-08-01 00:00:00

  • CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.

    abstract::CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401179

    authors: van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

    更新日期:1998-11-01 00:00:00

  • Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

    abstract::Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.194

    authors: Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

    更新日期:2013-12-01 00:00:00

  • Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.

    abstract::The transcription factor CCAAT/enhancer binding protein a (C/EBPalpha) is important in the regulation of granulopoiesis and is disrupted in human acute myeloid leukemia. In the present study, we sought to identify novel C/EBPalpha interacting proteins in vivo through immunoprecipitation using mass spectrometry-based p...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404438

    authors: Zada AA,Pulikkan JA,Bararia D,Geletu M,Trivedi AK,Balkhi MY,Hiddemann WD,Tenen DG,Behre HM,Behre G

    更新日期:2006-12-01 00:00:00

  • Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.

    abstract::Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401559

    authors: Corradini P,Ladetto M,Pileri A,Tarella C

    更新日期:1999-11-01 00:00:00

  • Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

    abstract::Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and T cells, transcription of GC-regulated genes was not rhythmic and the synthetic GC dexamethasone (DEX) could n...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0381-4

    authors: Shi Y,Wang G,Muhowski EM,McCaw L,Wang C,Bjarnason G,Woyach JA,Spaner DE

    更新日期:2019-07-01 00:00:00

  • Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.

    abstract::Retroviral gene transfer into hematopoietic cells has many experimental as well as clinical applications. Although transduction efficiency of retroviral vectors is higher than with conventional methods, selection of successfully transduced cells may become mandatory for efficient in vivo transfer. We have been evaluat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Flasshove M,Banerjee D,Bertino JR,Moore MA

    更新日期:1995-10-01 00:00:00

  • Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.

    abstract::The human factor-dependent leukemia cell line UCSD/AML1 contains the t(3;3) (q21;q26) characteristic of the syndrome of acute leukemia with high platelets. The human homologue of the murine leukemia oncogene evi-1 was recently localized to chromosome 3q24-3q28 and transcription of evi-1 is a frequent event in mouse-re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Oval J,Smedsrud M,Taetle R

    更新日期:1992-05-01 00:00:00

  • Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML.

    abstract::t(8;21)(q22;q22) is the most frequently observed karyotypic abnormality associated with acute myeloid leukemia (AML), especially in FAB M2. Clinically, this type of AML often shows eosinophilia and has a high complete remission rate with conventional chemotherapy. t(8;21) AML is also frequently associated with additio...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2402871

    authors: Nishii K,Usui E,Katayama N,Lorenzo F 5th,Nakase K,Kobayashi T,Miwa H,Mizutani M,Tanaka I,Nasu K,Dohy H,Kyo T,Taniwaki M,Ueda T,Kita K,Shiku H

    更新日期:2003-04-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract::This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.173

    authors: Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期:2017-12-01 00:00:00

  • Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia.

    abstract::Three cell populations with different DNA indices were demonstrated in a case of biphenotypic terminal transferase (TdT)/myeloid-positive acute leukemia which had developed from a pre-leukemic diploid population also expressing biphenotypic features. At the time of development of acute leukemia, flow-cytometric analys...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Paietta E,Andreeff M,Papenhausen P,Gucalp R,Wiernik PH

    更新日期:1989-01-01 00:00:00

  • Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.

    abstract::Heterozygous and homozygous deletions of chromosome 13q14.3 are found in 50% of patients with B cell CLL, suggesting the presence of one or more tumour suppressor genes within the deleted region. To identify candidate genes from the region, we constructed a map of 13q14.3 using a combination of genomic and cDNA librar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402551

    authors: Rowntree C,Duke V,Panayiotidis P,Kotsi P,Palmisano GL,Hoffbrand AV,Foroni L

    更新日期:2002-07-01 00:00:00

  • The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells.

    abstract::The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Fenstermaker RA,Capala J,Barth RF,Hujer A,Kung HJ,Kaetzel DM Jr

    更新日期:1995-10-01 00:00:00

  • Quantitative analysis of Op18 phosphorylation in childhood acute leukemia.

    abstract::Oncoprotein 18 (Op18) is a major cystolic phosphoprotein constituent of leukemia cells. There is cumulative evidence that suggests a role for Op18 in integrating signals from diverse pathways involved in cell growth. Op18 phosphorylation is induced with proliferation in a variety of cell types, and is essential for ce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400792

    authors: Melhem R,Hailat N,Kuick R,Hanash SM

    更新日期:1997-10-01 00:00:00

  • Acute myeloblastic leukemia with t(8;21) following Philadelphia positive acute lymphoblastic leukemia.

    abstract::A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

    更新日期:1989-04-01 00:00:00

  • The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

    abstract::The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation o...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2015.113

    authors: Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

    更新日期:2015-08-01 00:00:00

  • Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

    abstract::The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.10

    authors: Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

    更新日期:2013-06-01 00:00:00

  • Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993.

    abstract::A consecutive population-based series of 372 adult acute myeloid leukemias, successfully cytogenetically investigated at a single center between 1976 and 1993, is reported. All medical records were reviewed in order to ascertain the prognostic impact of karyotype, divided into three groups; favorable (t(8;21), t(15;17...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401788

    authors: Mauritzson N,Johansson B,Albin M,Rylander L,Billström R,Ahlgren T,Mikoczy Z,Strömberg U,Mitelman F,Hagmar L,Nilsson PG

    更新日期:2000-06-01 00:00:00

  • Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.

    abstract::Monitoring of BCR-ABL transcripts has become established practice in the management of chronic myeloid leukemia. However, nucleic acid amplification techniques are prone to variations which limit the reliability of real-time quantitative PCR (RQ-PCR) for clinical decision making, highlighting the need for standardizat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404716

    authors: Saldanha J,Silvy M,Beaufils N,Arlinghaus R,Barbany G,Branford S,Cayuela JM,Cazzaniga G,Gonzalez M,Grimwade D,Kairisto V,Miyamura K,Lawler M,Lion T,Macintyre E,Mahon FX,Muller MC,Ostergaard M,Pfeifer H,Saglio G,Saw

    更新日期:2007-07-01 00:00:00

  • Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease.

    abstract::In all, 17 consecutive patients in hematological complete remission (HCR) of acute promyelocytic leukemia (APL) received allogeneic stem cell transplantation (SCT) from an HLA-identical sibling and were monitored by reverse transcriptase polymerase chain reaction of PML/RARalpha prior and after transplant. Median age ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403078

    authors: Lo-Coco F,Romano A,Mengarelli A,Diverio D,Iori AP,Moleti ML,De Santis S,Cerretti R,Mandelli F,Arcese W

    更新日期:2003-10-01 00:00:00

  • Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

    abstract::Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.88

    authors: Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

    更新日期:2017-11-01 00:00:00

  • Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) stu

    abstract::Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2013.219

    authors: Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

    更新日期:2013-10-01 00:00:00

  • A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

    abstract::Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for counseling, choice of therapy and the design and interpretation of clinical investigation. Indeed, as in acute le...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404516

    authors: Stewart AK,Bergsagel PL,Greipp PR,Dispenzieri A,Gertz MA,Hayman SR,Kumar S,Lacy MQ,Lust JA,Russell SJ,Witzig TE,Zeldenrust SR,Dingli D,Reeder CB,Roy V,Kyle RA,Rajkumar SV,Fonseca R

    更新日期:2007-03-01 00:00:00

  • Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.

    abstract::Previous studies demonstrated that triazene compounds (TZC) possess antitumor, antimetastatic and immunosuppressive activity, and induce novel antigenic properties in neoplastic cells. Moreover, TZC showed marked antitumor activity in patients with acute myelogenous leukemias (AML). In most cases leukemic blasts with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Tentori L,Graziani G,Gilberti S,Lacal PM,Bonmassar E,D'Atri S

    更新日期:1995-11-01 00:00:00

  • Hematopoietic differentiation of umbilical cord blood-derived very small embryonic/epiblast-like stem cells.

    abstract::A population of CD133(+)Lin(-)CD45(-) very small embryonic/epiblast-like stem cells (VSELs) has been purified by multiparameter sorting from umbilical cord blood (UCB). To speed up isolation of these cells, we employed anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor to detect aldehyde dehy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.73

    authors: Ratajczak J,Zuba-Surma E,Klich I,Liu R,Wysoczynski M,Greco N,Kucia M,Laughlin MJ,Ratajczak MZ

    更新日期:2011-08-01 00:00:00

  • Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

    abstract::ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ((32)P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the long-term safety of hy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402638

    authors: Bernasconi P,Boni M,Cavigliano PM,Calatroni S,Brusamolino E,Passamonti F,Volpe G,Pistorio A,Giardini I,Rocca B,Caresana M,Lazzarino M,Bernasconi C

    更新日期:2002-10-01 00:00:00